Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 660-668

  Harbo, Hanne F ^a,b   Isobe, Noriko ^c   Berg Hansen, Pål ^a,b   Bos, Steffan D ^a,b   Caillier, Stacy J ^c   Gustavsen, Marte W ^a,b   Mero, Inger Lise ^a   Celius, Elisabeth Gulowsen ^a   Hauser, Stephen L ^c   Oksenberg, Jorge R ^c   Gourraud, Pierre Antoine ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age of onset; cerebrospinal fluid; genetic association; genetic risk; genotype; multiple sclerosis; Multiple Sclerosis Genetic Burden; oligoclonal bands

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; OLIGOCLONAL BAND; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADULT; ARTICLE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONTROLLED STUDY; EUROPEAN AMERICAN; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PHENOTYPE; SECOND DEGREE RELATIVE; SINGLE NUCLEOTIDE POLYMORPHISM; DISEASE SEVERITY ASSESSMENT; GENETIC ASSOCIATION; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS GENETIC BURDEN SCORE; MULTIPLE SCLEROSIS SEVERITY SCORE; NORWEGIAN (PEOPLE); POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; GENETIC SCREENING; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; FEMALE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84899048957     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513506503     Document Type: Article

References (28)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
2. Gourraud PA, Harbo HF, Hauser SL, et al. The genetics of multiple sclerosis: An up-to-date review. Immunol Rev. 2012 ; 248: 87-103
3. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
4. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 ; 41: 776-782
5. Patsopoulos NA, Esposito F, Reischl J, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 ; 70: 897-912
6. Gourraud PA, Sdika M, Khankhanian P, et al. A genome-wide association study of brain lesion distribution in multiple sclerosis. Brain. 2013 ; 136: 1012-1024
7. Gourraud PA, McElroy JP, Caillier SJ, et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol. 2011 ; 69: 65-74
8. Smestad C, Sandvik L, Holmoy T, et al. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol. 2008 ; 255: 49-55
9. Cree BA, Rioux JD, McCauley JL, et al. A Major Histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One. 2010 ; 5: e11296
10. Lorentzen AR, Karlsen TH, Olsson M, et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol. 2009 ; 65: 658-666
11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
13. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
14. Mero IL, Gustavsen MW, Saether HS, et al. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLoS One. 2013 ; 8: e58352
15. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry. 1994 ; 57: 897-902
16. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. J Neuroimmunol. 2006 ; 180: 17-28
17. Lechner-Scott J, Spencer B, De MT, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler. 2012 ; 18: 974-982
18. Rinker JR, Trinkaus K, Naismith RT, et al. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology. 2007 ; 69: 68-72
19. Balnyte R, Rastenyte D, Uloziene I, et al. The significance of HLA DRB1*1501 and oligoclonal bands in multiple sclerosis: Clinical features and disability. Medicina (Kaunas). 2011 ; 47: 368-373
20. Idiman E, Ozakbas S, Dogan Y, et al. The significance of oligoclonal bands in multiple sclerosis: Relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol. 2009 ; 212: 121-124
21. Imrell K, Landtblom AM, Hillert J, et al. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurology. 2006 ; 67: 1062-1064
22. Imrell K, Greiner E, Hillert J, et al. HLA-DRB115 and cerebrospinal fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol. 2009 ; 210: 128-130
23. Joseph FG, Hirst CL, Pickersgill TP, et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients. J Neurol Neurosurg Psychiatry. 2009 ; 80: 292-296
24. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci. 2009 ; 279: 21-25
25. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology. 2007 ; 68: 376-383
26. Masterman T, Ligers A, Olsson T, et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000 ; 48: 211-219
27. Smestad C, Brynedal B, Jonasdottir G, et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol. 2007 ; 14: 835-840
28. Celius EG, Harbo HF, Egeland T, et al. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000 ; 178: 132-135